Drug wars : how big pharma raises prices and keeps generics off the market / Robin Feldman, Evan Frondorf.
Publisher: New York, NY : Cambridge University Press, 2017Description: p. ; cmContent type:- text
- unmediated
- volume
- 9781107168480 (hardback)
- 338.4/76151 23
- RA401.A3 F45 2017
- QV 736 AA1
Item type | Current library | Shelving location | Call number | Copy number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|---|
Book | NMC Library | Stacks | RA401 .A3 F45 2017 (Browse shelf(Opens below)) | 1 | Available | 33039001430676 |
Browsing NMC Library shelves, Shelving location: Stacks Close shelf browser (Hides shelf browser)
No cover image available | ||||||||
RA399 .A1 G39 2010 The checklist manifesto : how to get things right / | RA399 .A1 K46 2008 The best practice : how the new quality movement is transforming medicine / | RA399.5 .D85 2013 Pandemics / | RA401 .A3 F45 2017 Drug wars : how big pharma raises prices and keeps generics off the market / | RA407.3 .U5 2019 Health, United States, 2009 : in brief / | RA408 .A3 H65 2011 Ethics, aging, and society : the critical turn / | RA408.5 .A33 2006 Designing and conducting health surveys : a comprehensive guide / |
Includes bibliographical references and index.
Machine generated contents note: Introduction: big scandals, higher prices; 1. The winding road to generic entry; 2. 'Generation 1.0': the rise and fall of traditional pay-for-delay; 3. 'Generation 2.0': complicating pay-for-delay; 4. 'Generation 3.0': new tactics for active obstruction of generics; 5. 'Generation 3.0' continued: obstruction of regulatory pathways; 6. Empirical evidence of a citizen's pathway gone astray; Conclusion: a call for systematic reform.
"While the shockingly high prices of prescription drugs continue to dominate the news, the strategies used by pharmaceutical companies to prevent generic competition are poorly understood, even by the lawmakers responsible for regulating them. In this groundbreaking work, Robin Feldman and Evan Frondorf illuminate the inner workings of the pharmaceutical market and show how drug companies twist health policy to achieve goals contrary to the public interest. In highly engaging prose, they offer specific examples of how generic competition has been stifled for years, with costs climbing into the billions and everyday consumers paying the price. Drug Wars is a guide to the current landscape, a roadmap for reform, and a warning of what is to come. It should be read by policymakers, academics, patients, and anyone else concerned with the soaring costs of prescription drugs"--Provided by publisher.